SENTI-202 is the Company’s first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 ...

**media [658231]**SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 ...

SENTI-202 is the Company's first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 ...

Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing ...

The Company’s lead program, SENTI-202, is a first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 ...

Key Takeaways SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy ...

Introduction of SENTI-202, a first-in-class off-the-shelf CAR NK cell therapy targeting hematologic malignancies, which highlights the innovative capacity of the company's Gene Circuit platform.

FEATURED UW Libraries is improving your library experience by implementing Radio Frequency Identification (RFID) tags across our physical collections. This upgrade will make self-checkout faster, ...

This wind is starting to feel like the Wild West. What if you just immersed yourself in that rugged environment willingly with a Western? William Johnstone (Colton Gray: Depute US Marshal; Halfway to ...

Synopsys’ IP D-PHY IP enables high-performance, low-power interface to SoCs, application processors, baseband processors, and peripheral devices for mobile, automotive, artificial intelligence (AI), ...